SCCA Clinical Studies: Lung Cancer
LDK378 for Tumors with ALK Mutation (UW10038)
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
| Status | Conditions | Phase | Study ID |
| Recruiting | Tumors Characterized by Genetic Abnormalities of ALK | Phase I |
(UW10038) NCT01283516 |
Summary
This study will assess the safety and early efficacy of LDK378 in patients with genetic abnormalities in anaplastic lymphoma kinase (ALK).
|
|
Eligibility Criteria (must meet the following to participate in this study)
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
• Tumor must be confirmed to be ALK positive
Exclusion Criteria:
- Pregnant
- Active pancreatitis
- Active or chronic liver disease
Other protocol-defined inclusion/exclusion criteria may apply
Last Updated
April 28, 2011See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.